EGFR-targeting ADCs: From oncogene addiction to antigen-guided drug delivery.

EGFR-targeting antibody-drug conjugate SYS6010 shows potential in advanced solid tumors, marking a shift from kinase inhibition to antigen-guided drug delivery in non-small cell lung cancer.

• Why it matters: Understanding new therapeutic approaches is crucial as resistance to kinase inhibitors limits current EGFR-targeted treatments in non-small cell lung cancer, necessitating alternative strategies.
• What they did: Li et al. conducted a first-in-human phase 1 study of SYS6010, an EGFR-targeting antibody-drug conjugate, in patients with advanced solid tumors, including non-small cell lung cancer.
• The result: The study demonstrates the feasibility of antigen-guided cytotoxic delivery targeting EGFR, which may expand treatment options beyond kinase inhibition for EGFR-positive cancers.